Latest news
Debiopharm Investment strengthens its presence in the renewable energy sector
GenePOC to Announce CE Marking of its revogene™ Instrument and its Second Test, CDiff
Debiopharm International SA Announces positive Phase 2 Clinical Trial with Debio 1450 in ABSSSI patients
Debiopharm Group’s Triptorelin 6-month Formulation Receives Approval for the Treatment of Central Precocious Puberty (CPP) in Europe
Les projets «Hello Mask» et «Le 5ème mur» remportent le Challenge Debiopharm-Inartis 2016 sur la Qualité de Vie des Patients
GenePOC announces setup of an extensive network of commercial partners across Europe for Distribution
Debiopharm International SA Reaches Important Development Milestones for its Staphylococcus-selective antibiotic Debio 1450
Debiopharm International SA Announces Clinical Collaboration with the Merck-Pfizer Alliance in Cancer Immunotherapy